With first-class skills and rich experience, Creative Biolabs offers services for generation and validation of chimeric T cell receptor (chTCR), which is an attractive strategy to genetically modify and redirect the specificity of T cells in adoptive immunotherapy.
Figure, Chimeric T cell receptor. A, Strategies for chTCR; B, A typical chimeric receptor.
Genetically-modified T lymphocytes expressing T cell receptors (chTCR) specific for tumor cells have been widely investigated for cancer therapy. chTCR is an approach that uses the gene encoding modified TCR or monoclonal antibody chains to endow the TCR with high affinity to tumor associated antigens (TAAs). Typically, chTCR consists of three functional regions: extracellular domains, transmembrane domains and intracellular signaling domains. The extracellular fragments made from TCR or tumor-specific antibody are designed to recognize and bind target cells such as cancer cells. As shown in the figure A, the TCR can be conventional or a single chain and the specific antibody can be Fab or single-chain variable fragment (scFv). ScFv is used more frequently than Fab in recent researches. Transmembrane domain is important to overcome the mispairing of chTCR with endogenous TCR chains. To proliferate and respond on an antigen, T cells relies on the co-stimulatory signals. Accordingly, the transmembrane and intracellular signaling domains may be derived from primary activation molecules, co-stimulatory molecules and intracellular protein kinases, such as CD3ζ or FcεRI. A hinge is constructed for linking the extracellular fragments and signaling domains. Additionally, the modification of primary human T cells from healthy donors could be used to generate humanized chTCR (hchTCR) speciﬁc for adoptive T cell immunotherapy for cancers. As the chTCR is not restricted by MHC molecules which natural TCR depends on the generated supernatural T cells can be an ideal tool in cancer therapy.
Creative Biolabs have professional experts from different disciplines to ensure the construction of robust and reliable chimeric receptors targeting your concerned antigens.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE